Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Summary

Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Timeline

Start

2024-10-10

Primary completion

2028-04

Completion

2029-01

Drugs

Indications